Food and Drug Administration

Anti-Infective Drugs Advisory Committee

September 12, 2006

Briefing Information

FDA

FDA Backgrounder (pdf)

FDA Briefing Document Addendum and Errata from Division of Special Pathogen and Transplant Products (pdf)

FDA Briefing Document Addendum from Division of Drug Risk Evaluation (pdf)

 FDA Bibliography (pdf)

Oscient Pharmaceuticals Corporation

Disclaimer

The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.

Briefing Material (pdf)

Errata (pdf)